A new national survey by the Orlando Health Cancer Institute finds nearly a third (32%) of Americans agree that a tan makes people look better and healthier, a dangerous beauty… read more.
AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once… read more.
Giving GPs cameras to photograph skin complaints could help slash wait times for hospital appointments according to a new service evaluation from the University of East Anglia. An… read more.
Arcutis Biotherapeutics, Inc., highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis . The Arcutis sponsored research from The Kimberly and… read more.
Arcutis Biotherapeutics, Inc. and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, announced that the companies have entered into a strategic collaboration and licensing agreement for the development,… read more.
Regeneron Pharmaceuticals, Inc. announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of… read more.
Arcutis Biotherapeutics, Inc. announced that the Journal of American Academy of Dermatology (JAAD) published positive results from the pivotal Phase III STRATUM trial evaluating Zoryve (roflumilast) foam, 0.3%… read more.
New research indicates that higher doses of topical corticosteroids, which are commonly used to treat inflammatory skin conditions, are linked with elevated risks of osteoporosis and bone fractures… read more.
Arcutis Biotherapeutics, Inc. announced the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9… read more.
Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced that the FDA has approved the New Drug Application for Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide)… read more.
Almost half (42%) of patients with skin disease experience sleep disturbances, a major study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2023 has… read more.
Skin cancer detection using artificial intelligence (AI) software has rapidly improved, new research has shown, with the latest software reaching a 100% detection rate for melanoma.1 The study,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
